title: Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
abstract: To evaluate the efficacy of imatinib in a practical setting, we registered 43 patients with newly diagnosed chronic myelogenous leukemia (CML) (group I) and 56 patients with previously diagnosed CML (group II) at 11 hematology centers in Nagasaki prefecture, Japan, from December 2001 to July 2005 and analyzed the molecular responses. Cytopenia, fluid retention, and skin rash were major adverse events, along with elevation in creatine phosphokinase levels. With a follow-up of approximately 3.5 years, imatinib treatment led to 88.7% overall survival (OS) and 85.2% progression-free survival (PFS) rates for group I, and 79.8% OS and 76.6% PFS rates for group II; the rates were not significantly different despite a lower average imatinib dose in group II. The rates of complete cytogenetic response at 30 months and major molecular response at 24 months were 86.1% and 62.5%, respectively, in group I, and 77.9% and 58.3% in group II; the rates were not significantly different. As has been reported by other groups, these results demonstrate that imatinib treatment can provide excellent clinical and molecular effects for not only newly diagnosed but also previously treated CML patients in practical settings that cover a wider variety of patients than clinical trials.
authors.affiliation: Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
authors.forename: Emi
authors.initials: E
authors.lastname: Matsuo
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Chizuko
authors.initials: C
authors.lastname: Tsutsumi
authors.forename: Yoriko
authors.initials: Y
authors.lastname: Inoue
authors.forename: Reishi
authors.initials: R
authors.lastname: Yamasaki
authors.forename: Tomoko
authors.initials: T
authors.lastname: Hata
authors.forename: Takuya
authors.initials: T
authors.lastname: Fukushima
authors.forename: Hideki
authors.initials: H
authors.lastname: Tsushima
authors.forename: Daisuke
authors.initials: D
authors.lastname: Imanishi
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Imaizumi
authors.forename: Masako
authors.initials: M
authors.lastname: Iwanaga
authors.forename: Mari
authors.initials: M
authors.lastname: Sakai
authors.forename: Koji
authors.initials: K
authors.lastname: Ando
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sawayama
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ogawa
authors.forename: Yasuhisa
authors.initials: Y
authors.lastname: Kawaguchi
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nagai
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Tsukasaki
authors.forename: Shuichi
authors.initials: S
authors.lastname: Ikeda
authors.forename: Yukiyoshi
authors.initials: Y
authors.lastname: Moriuchi
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Yoshida
authors.forename: Miyuki
authors.initials: M
authors.lastname: Honda
authors.forename: Jun
authors.initials: J
authors.lastname: Taguchi
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Onimaru
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tsuchiya
authors.forename: Masayuki
authors.initials: M
authors.lastname: Tawara
authors.forename: Sunao
authors.initials: S
authors.lastname: Atogami
authors.forename: Masaomi
authors.initials: M
authors.lastname: Yamamura
authors.forename: Hisashi
authors.initials: H
authors.lastname: Soda
authors.forename: Yoshiharu
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Yuji
authors.initials: Y
authors.lastname: Matsuo
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nonaka
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Joh
authors.forename: Yumi
authors.initials: Y
authors.lastname: Takasaki
authors.forename: Chiyuki
authors.initials: C
authors.lastname: Kawasaki
authors.forename: Saburo
authors.initials: S
authors.lastname: Momita
authors.forename: Itsuro
authors.initials: I
authors.lastname: Jinnai
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Kuriyama
authors.forename: Masao
authors.initials: M
authors.lastname: Tomonaga
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001549:Benzamides; D003402:Creatine Kinase / Q000097:blood; D020732:Cytogenetic Analysis; D018572:Disease-Free Survival; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D003402:Creatine Kinase